文献速递抗栓抗凝管理药物相互作用

四例退伍军人丙型肝炎治愈后华法林剂量需求变化

Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans.
PubMed 文献 · Pharmacotherapy · 2016-11-04

该病例系列描述了4例接受华法林抗凝的退伍军人(59-66岁)在启动雷迪帕韦/索磷布韦(联用或不联用利巴韦林)治疗丙型肝炎后的INR趋势和华法林剂量调整。所有4例患者均出现INR低于治疗范围,需增加华法林周剂量14%-67%,剂量调整始于开始治疗后2-3周;2例在HCV治疗完成后需减量。提示临床应密切监测华法林抗凝患者。

要点

  • 启动雷迪帕韦/索磷布韦后2-3周内可能出现INR下降,需增加华法林周剂量14%-67%。
  • HCV治疗完成后部分患者需减量华法林,应监测INR至稳定。
  • 肝硬化患者风险可能更高,治疗首月及完成后首月需加强监测。

核心结论

  • 雷迪帕韦/索磷布韦(联用或不联用利巴韦林)与华法林可能存在药物相互作用,导致INR下降和华法林剂量需求增加。
  • 在启动雷迪帕韦/索磷布韦的华法林抗凝患者中,尤其是有肝硬化证据者,应密切监测INR。

研究设计与样本

  • 病例系列研究,纳入4例年龄59-66岁、接受华法林且INR稳定在治疗范围的退伍军人,启动雷迪帕韦/索磷布韦(联用或不联用利巴韦林)治疗HCV感染。
  • 研究设置于退伍军人事务医疗系统的药师主导抗凝门诊。

主要发现

  • 所有4例患者加用雷迪帕韦/索磷布韦(联用或不联用利巴韦林)后均出现INR低于治疗范围。
  • 华法林周剂量需增加14%-67%,剂量调整始于开始雷迪帕韦/索磷布韦后2-3周。
  • 2例患者在HCV治疗完成后需减量华法林,另2例无需减量。
  • 药物相互作用概率量表评分显示,华法林与雷迪帕韦/索磷布韦的相互作用为可疑(2例,评分1)或可能(2例,评分4)。

临床怎么用

  • 对接受华法林抗凝的患者,在启动雷迪帕韦/索磷布韦治疗时,应在治疗首月及完成后首月密切监测INR,并根据结果调整华法林剂量。
  • 尤其对治疗前有肝硬化证据的患者,应加强INR监测。

局限性

  • 样本量小(4例),为病例系列研究,无法确定因果关系。
  • 相互作用机制尚不明确,可能与HCV治疗期间肝功能改善有关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: To describe international normalized ratio (INR) trends and warfarin dosage adjustments required for four veterans who were receiving warfarin therapy and started treatment for hepatitis C virus (HCV) with ledipasvir/sofosbuvir with or without ribavirin. DESIGN: Case series. SETTING: Pharmacist-led anticoagulation clinic in a Veterans Affairs Health Care System. PATIENTS: Four patients aged 59-66 years who were receiving warfarin and had stable, therapeutic INRs and started ledipasvir/sofosbuvir therapy with or without ribavirin for HCV infection. MEASUREMENTS AND MAIN RESULTS: All four patients developed subtherapeutic INRs after the addition of ledipasvir/sofosbuvir with or without ribavirin. An increase in weekly warfarin dose ranging from 14-67% was required, with changes in warfarin doses starting 2-3 weeks after ledipasvir/sofosbuvir initiation. Two patients required dose reductions after HCV treatment completion, whereas the other two did not. Use of the Drug Interaction Probability Scale indicated that the interaction between warfarin and ledipasvir/sofosbuvir was doubtful (score of 1 [two patients]) or possible (score of 4 [two patients]). The mechanism of this interaction is unknown but may be related to improvements in hepatic function during HCV treatment. CONCLUSION: To our knowledge, this is the first case series describing a possible drug interaction between warfarin and ledipasvir/sofosbuvir (with or without ribavirin). Close monitoring is warranted when ledipasvir/sofosbuvir is initiated in patients receiving anticoagulation therapy with warfarin, especially those with evidence of cirrhosis prior to treatment. This is particularly important in the first month after starting treatment and the first month after completion. Failure to monitor and achieve therapeutic INR after HCV therapy completion may have the potential to result in adverse outcomes.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Britnell SR, Willets AE, Vanderman AJ, et al. Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans. Pharmacotherapy. 2016. PMID: 27716978. doi:10.1002/phar.1845

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。